<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01510691</url>
  </required_header>
  <id_info>
    <org_study_id>VE-Oxygen-28062010</org_study_id>
    <nct_id>NCT01510691</nct_id>
  </id_info>
  <brief_title>Vitrectomy Retinal Oxygenation</brief_title>
  <official_title>The Influence of Retinal Oxygenation on the Clinical Outcomes in Eyes With Different Vitreoretinal Pathologies After a Successful Vitrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stefan Sacu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      Vitrectomy is the common treatment for patients with macular edema secondary to epiretinal&#xD;
      membrane. Recently, in eyes with diabetic macular edema or persistent macular edema following&#xD;
      retinal vein occlusion, vitrectomy will be increasingly performed as an additional treatment&#xD;
      modality. In eyes with impaired oxygen situation vitrectomy may improve the retinal oxygen&#xD;
      saturation. However, little information is available about the oxygenation and the blood flow&#xD;
      of the retinal vessels after vitroretinal surgery.&#xD;
&#xD;
      Hypoxia is a the major trigger of vascular endothelial growth factor (VEGF), which is in turn&#xD;
      the most important factor for the development of macular edema. It is a major issue to&#xD;
      improve the oxygen situation and the blood flow of the retina and there are just a few not&#xD;
      satisfactory procedures available to overcome this problem. However, vitrectomy would be an&#xD;
      adequate therapy for many of these diseases, and it would be an appreciated side effect of&#xD;
      the treatment in almost every case.&#xD;
&#xD;
      To investigate the influence of oxygenation and blood flow of the retina on clinical outcomes&#xD;
      after a successfully 23 gauge vitrectomy in eyes with epiretinal membrane, persistent macular&#xD;
      edema following diabetic retinopathy or retinal vein occlusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Difficulties in recruiting participants&#xD;
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Data</measure>
    <time_frame>6 months</time_frame>
    <description>Visus, OCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Flow Data</measure>
    <time_frame>6 months</time_frame>
    <description>Oxygenation of retinal blood vessles and retinal blood flow</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Epiretinal membrane</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetic macular edema</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>vein occlusion</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Group 1: 20 patients with macular edema following epiretinal membrane Group 2: 20 patients&#xD;
        with persistent diabetic macular edema. Group 3: 20 patients with persistent macular edema&#xD;
        following retinal vein occlusion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female, at least 18 years of age.&#xD;
&#xD;
          -  ophthalmoscopic evidence of epiretinal membrane scheduled for vitrectomy and membrane&#xD;
             peeling.&#xD;
&#xD;
          -  persistent diabetic macular edema&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  female patients of childbearing potential must have a negative urine pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncontrolled systemic disease&#xD;
&#xD;
          -  symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  any ocular condition that in the opinion of the investigator would be a&#xD;
             contraindication for the surgical procedure&#xD;
&#xD;
          -  history of glaucoma, aphakie or presence of anterior chamber intraocular lens,&#xD;
             choroidal neovascularisation, significant cataract, any ocular infection, - history of&#xD;
             pars plana vitrectomy.&#xD;
&#xD;
          -  contraindication to pupil dilation.&#xD;
&#xD;
          -  need for silicon oil or gas after the surgery&#xD;
&#xD;
          -  advanced diabetic retinopathy with vitreoretinal tear and/or bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Opthalmology/Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 11, 2012</study_first_submitted>
  <study_first_submitted_qc>January 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2012</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Stefan Sacu</investigator_full_name>
    <investigator_title>Ass Prof Priv Doz Dr</investigator_title>
  </responsible_party>
  <keyword>Oxygenation of the retinal vessels</keyword>
  <keyword>vitroretinal surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

